Successful 13‐year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27461 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Mariam A Mostafa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rochester General Hospital, Rochester, New York, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Atypical Hemolytic Uremic Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rochester General Hospital, Rochester, New York, USA.
- Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- University of Rochester, Rochester, New York, USA.
- Roswell Park Memorial Cancer Institute, Rochester General Hospital, University of Rochester, Rochester, New York, USA.
ORCID-Profile: Mariam A Mostafa
Zitieren
APA
Mostafa, M. A., Zand, M., Taylor, J., & Kouides, P. (2024). Successful 13‐year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome. American Journal of Hematology. https://doi.org/10.1002/ajh.27461
Vancouver
Mostafa MA, Zand M, Taylor J, Kouides P. Successful 13‐year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome. American Journal of Hematology. 2024. doi:10.1002/ajh.27461
BibTeX
@article{Mostafa2024,
author = {Mostafa, Mariam A and Zand, Martin and Taylor, Jeremy and Kouides, Peter},
title = {Successful 13‐year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27461}
}
EUVIMED